Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.201
-0.009 (-4.29%)
At close: Apr 28, 2026, 4:00 PM EDT
0.200
-0.001 (-0.50%)
After-hours: Apr 28, 2026, 7:31 PM EDT
Sangamo Therapeutics Employees
Sangamo Therapeutics had 142 employees as of December 31, 2025. The number of employees decreased by 41 or -22.40% compared to the previous year.
Employees
142
Change (1Y)
-41
Growth (1Y)
-22.40%
Revenue / Employee
$278,535
Profits / Employee
-$865,718
Market Cap
83.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Gossamer Bio | 162 |
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| PolyPid | 75 |
| Rani Therapeutics Holdings | 71 |
| eXoZymes | 32 |
| Q32 Bio | 24 |
SGMO News
- 4 weeks ago - Sangamo Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call - GlobeNewsWire
- 7 weeks ago - Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire
- 3 months ago - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 - GlobeNewsWire
- 3 months ago - Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering - GlobeNewsWire
- 4 months ago - Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - GlobeNewsWire
- 5 months ago - Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - GlobeNewsWire